BIOMAT Database Logo BIOMAT Database Logo

Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. 1997

A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Laboratory of Clinical Science, National Institute of Mental Health, NIH Clinical Science Center, Bethesda, MD 20892, USA.

Several serotonin3 (5-HT3) antagonists have been shown to attenuate the anxiogenic effects of the serotonergic agent, m-chlorophenylpiperazine (m-CPP), in animal models, but little data regarding possible effects of 5-HT3 antagonists on responses to m-CPP are available from studies in humans. Therefore, we studied the behavioral, physiological and neuroendocrine responses of 12 healthy volunteers to i.v. administered placebo and m-CPP (0.08 mg/kg), with and without i.v. pretreatment with the selective 5-HT3 antagonist, ondansetron (0.15 mg/kg). Compared to placebo, m-CPP given alone significantly increased ratings of anxiety and several other behavioral measures. m-CPP also produced statistically significant increases in temperature, systolic and diastolic blood pressure, heart rate, and in plasma concentrations of adrenocorticotropic hormone, cortisol, prolactin and norepinephrine. Responses to ondansetron given alone were no different from those of placebo. Pretreatment with ondansetron did not affect peak behavioral responses to m-CPP, but was associated with a significantly earlier return to baseline levels of ratings of anxiety and functional deficit as well as a summary measure of overall behavioral effects. Following ondansetron pretreatment, the increases produced by m-CPP in systolic and diastolic blood pressure and heart rate were no longer significantly different from placebo. Ondansetron pretreatment significantly reduced their plasma cortisol response to m-CPP without affecting the other plasma hormone responses. Plasma concentrations of m-CPP were unaffected by ondansetron pretreatment. These findings suggest that in normal human subjects some behavioral, cardiovascular and neuroendocrine effects of m-CPP may be partially modulated by 5-HT3 receptor-mediated mechanisms.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D009490 Neurosecretory Systems A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ. Neuroendocrine System,Neuroendocrine Systems,Neurosecretory System,System, Neuroendocrine,System, Neurosecretory,Systems, Neuroendocrine,Systems, Neurosecretory
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D005059 Euphoria An exaggerated feeling of physical and emotional well-being not consonant with apparent stimuli or events; usually of psychologic origin, but also seen in organic brain disease and toxic states. Euphorias
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Hormonal responses to meta-chlorophenylpiperazine (m-CPP) are undiminished by acute m-CPP pretreatment.
May 1996, Psychiatry research,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
March 1998, Biological psychiatry,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
January 1992, Archives of general psychiatry,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners.
February 1999, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects.
January 1997, The American journal of psychiatry,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
November 1994, The American journal of psychiatry,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
November 1999, Psychopharmacology,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia.
November 1992, Archives of general psychiatry,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.
January 1993, Psychopharmacology,
A Broocks, and N C Briggs, and T A Pigott, and J L Hill, and S K Canter, and T J Tolliver, and D Baldemore, and D L Murphy
Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.
January 1989, Psychopharmacology,
Copied contents to your clipboard!